Verve Therapeutics
Stock Forecast, Prediction & Price Target
Verve Therapeutics (VERV) stock Price Target by analysts
$14
Potential upside: 25.00%
Verve Therapeutics price prediction
What is Verve Therapeutics stock analysts` prediction?
Verve Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Verve Therapeutics in the last 3 months, the avarage price target is $14, with a high forecast of $NaN. The average price target represents a 25.00% change from the last price of $11.2.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Verve Therapeutics stock Price Target by analysts
Full breakdown of analysts given Verve Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Mitchell Kapoor H.C. Wainwright | 0% 0/1 | 10 months ago | $14 25.00% upside | $6.32 | StreetInsider | Previous targets (0) |
Kostas Biliouris BMO Capital | 0% 0/1 | over 1 year ago | $30 167.85% upside | $8.57 | StreetInsider | Previous targets (0) |
Unknown Goldman Sachs | N/A | over 2 years ago | $13 16.07% upside | $22.61 | Benzinga | N/A |
Verve Therapeutics Financial Estimates
Verve Therapeutics Revenue Estimates
Verve Therapeutics EBITDA Estimates
Verve Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $1.94M 0% | $11.75M 505.77% | Avg: $11.36M Low: $7.57M High: $15.15M avg. -3.36% | Avg: $20.52M Low: $10.76M High: $44.48M avg. 80.59% | Avg: $12.85M Low: $6.74M High: $27.86M avg. -37.37% | Avg: $58.45M Low: $30.66M High: $126.72M avg. 354.86% |
Net Income
% change YoY
| $-118.63M N/A | $-157.38M -32.66% | $-200.06M -27.11% | Avg: $-260.47M Low: $-206.64M High: $-144.39M avg. -30.19% | Avg: $-283.25M Low: $-224.61M High: $-136.05M avg. -8.74% | Avg: $-216.69M Low: $-545.76M High: $-82.80M avg. 23.49% | Avg: $-216.48M Low: $-545.22M High: $-82.71M avg. 0.09% |
EBITDA
% change YoY
| $-87.06M N/A | $-162.88M -87.07% | $-217.66M -33.63% | Avg: $2.27M Low: $1.51M High: $3.02M avg. 101.04% | Avg: $4.10M Low: $2.15M High: $8.89M avg. 80.59% | Avg: $2.56M Low: $1.34M High: $5.57M avg. -37.37% | Avg: $11.68M Low: $6.13M High: $25.34M avg. 354.86% |
EPS
% change YoY
| -$2.45 N/A | -$2.91 -18.77% | -$3.12 -7.21% | Avg: -$2.84 Low: -$3.22 High: -$2.25 avg. 8.90% | Avg: -$2.79 Low: -$3.5 High: -$2.12 avg. 1.69% | Avg: -$3.38 Low: -$8.5 High: -$1.29 avg. -20.85% | Avg: -$3.37 Low: -$8.5 High: -$1.29 avg. 0.09% |
Operating Expenses
% change YoY
| $87.06M N/A | $167.62M 92.52% | $234.88M 40.12% | Avg: $59.35M Low: $39.57M High: $79.14M avg. -74.72% | Avg: $107.19M Low: $56.24M High: $232.41M avg. 80.59% | Avg: $67.12M Low: $35.22M High: $145.54M avg. -37.37% | Avg: $305.34M Low: $160.21M High: $662.01M avg. 354.86% |
FAQ
What is Verve Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -3.83% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -206.64M, average is -260.47M and high is -144.39M.
What is Verve Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 98.67% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $7.57M, average is $11.36M and high is $15.15M.
What is Verve Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -2.53% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$3.22, average is -$2.84 and high is $-2.25.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Verve Therapeutics stock. The most successful analyst is Mitchell Kapoor.